Teva (TEVA) CFO pre-planned sale of 153,251 shares reported in Form 4

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD Executive Vice President and Chief Financial Officer Eliyahu Sharon Kalif reported an open-market sale of 153,251 Ordinary Shares on May 14, 2026 at a weighted average price of $35.6107 per share. The shares were sold in multiple trades between $35.59 and $35.80. After the sale, he directly holds 172,184 Ordinary Shares, indicating he retains a substantial equity stake. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan, meaning the trade was scheduled in advance rather than timed discretionarily.

Insights

Equity compensation and insider-trading analyst

Pre-planned, sizable CFO sale but significant holdings remain.

The filing shows Teva’s CFO executed an open-market sale of 153,251 shares of Ordinary Shares at a weighted average price of $35.6107. This is a meaningful personal liquidity event, yet he continues to hold 172,184 shares directly.

A key detail is that the sale occurred under a pre-arranged Rule 10b5-1 trading plan, adopted in advance. Such plans automate trades and reduce the informational content of timing, framing this as routine portfolio management rather than a discretionary market-timing decision.

The transaction involves only non-derivative shares, with no remaining derivative positions listed in this filing. Subsequent company filings may clarify any future plan-driven transactions or changes in the executive’s equity exposure over later periods.

Insider Trade Summary 10b5-1

Net Seller: 153,251 shares ($5,457,375)

Net Sell 1 txn

Insider Kalif Eliyahu Sharon

Role EVP, Chief Financial Officer

Sold 153,251 shs ($5.46M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	153,251	$35.6107	$5.46M

Holdings After Transaction: Ordinary Shares — 172,184 shares (Direct, null)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.59 to $35.80, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 153,251 shares Weighted average sale price: $35.6107 per share Price range: $35.59–$35.80 per share +3 more

6 metrics

Shares sold 153,251 shares Open-market sale on May 14, 2026

Weighted average sale price $35.6107 per share Ordinary Shares sold in multiple trades

Price range $35.59–$35.80 per share Range of individual sale transactions

Shares held after transaction 172,184 shares Direct holdings of Teva CFO post-sale

Net share direction 153,251 net shares sold Net-sell according to transaction summary

Trading plan adoption date November 26, 2025 Rule 10b5-1 plan for this sale

Key Terms

Rule 10b5-1 trading plan, American Depositary Shares, weighted average price, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalif Eliyahu Sharon

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	05/14/2026		S(2)		153,251	D	$35.6107(3)	172,184	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.59 to $35.80, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Teva (TEVA) report for its CFO?

Teva reported that its CFO, Eliyahu Sharon Kalif, sold 153,251 Ordinary Shares in an open-market transaction. The weighted average sale price was $35.6107 per share, with trades executed between $35.59 and $35.80, reflecting a sizable but structured personal share sale.

Was the Teva (TEVA) CFO share sale under a Rule 10b5-1 plan?

Yes. The filing states the CFO’s sale was executed under a Rule 10b5-1 trading plan adopted on November 26, 2025. Such pre-arranged plans schedule trades automatically, reducing the significance of trade timing as a signal of management’s short-term outlook.

How many Teva (TEVA) shares does the CFO hold after this sale?

Following the reported transaction, Teva’s CFO directly holds 172,184 Ordinary Shares. This figure reflects his remaining equity stake after selling 153,251 shares, indicating he still maintains a significant ownership position in the company despite the sizable sale.

At what prices did the Teva (TEVA) CFO sell his shares?

The sale’s reported weighted average price was $35.6107 per share. Footnotes explain the 153,251 shares were sold in multiple trades at prices ranging from $35.59 to $35.80, and detailed trade breakdowns are available on request from the reporting person.

What type of security did the Teva (TEVA) CFO sell in this Form 4?

The transaction involved Teva Ordinary Shares, which may be represented by American Depositary Shares, each currently representing one Ordinary Share. The filing specifies this was a non-derivative open-market sale, not an exercise or conversion of options or other derivatives.

Does the Teva (TEVA) Form 4 mention any remaining derivatives for the CFO?

No derivative positions are listed in the derivative section of this Form 4 for the CFO. The reported activity involves only non-derivative Ordinary Shares, with no options, warrants, or other derivative securities shown as exercised, converted, or remaining outstanding in this filing.